1. 1700 Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy (hev-na); an international multicentre retrospective comparative study
- Author
-
Richie G. Madden, Harry R. Dalton, Claudio Gobbi, Miriam Fritz, Giorgia Melli, P. Ripellino, J.J.J. van Eijk, Catherine Jones, and Emanuela Pasi
- Subjects
Neuralgic amyotrophy ,medicine.medical_specialty ,Demographics ,medicine.diagnostic_test ,business.industry ,viruses ,virus diseases ,medicine.disease_cause ,Gastroenterology ,digestive system diseases ,Psychiatry and Mental health ,Hepatitis E virus ,Internal medicine ,Genotype ,medicine ,Retrospective analysis ,Surgery ,Neurology (clinical) ,Clinical phenotype ,business ,Liver function tests ,Brachial plexus - Abstract
Background HEV-NA may have a distinct clinical phenotype and outcome compared to cases of NA without HEV infection. Methods Cases of NA were identified in 11 centres from 7 countries, with retrospective analysis of demographics, clinical/laboratory findings, treatment and outcome. HEV-NA cases were compared to NA cases without evidence of HEV infection. Findings 57 HEV-NA and 61 NA without HEV cases were studied. 56/57 of HEV-NA cases were IgM positive (53 IgG positive). In 36 HEV RNA was recovered from the serum and in one from the CSF (all genotype 3). 51/57 HEV-NA cases were anicteric (median ALT was 259 IU/L: range 12–2961). In 6 the liver function tests (LFT) were normal. HEV-NA cases were more likely to have bilateral involvement (p Interpretation Patients with HEV-NA are usually anicteric with modest rises in ALT and have a distinct clinical phenotype. Involvement outside the brachial plexus is more common. Patients presenting with NA should be tested for HEV, irrespective of LFT. Prospective treatment/outcome studies of HEV-NA are now warranted.
- Published
- 2017
- Full Text
- View/download PDF